新颖的疫苗是在玉米中生产的，通过饲料给药

6月9日World Pork Expo 2022in Des Moines, IA,里克·西贝尔博士， 和Mazen动物健康，宣布他的公司将越来越接近完成一种新型疫苗的开发玉米并通过动物饲料进行管理。

"My company is doing something that has never been done," said Sibbel during the Bacon & Innovation panel discussion at WPX.

"We've talked about it for 20 years, but it's never been done," he said. "We figured out through plant biology and immunology how to put protective antigens in the germ cell of corn, grow the corn, grind the corn and feed it to the pigs."

Transformative vaccine technology

牲畜的疫苗接种可防止疾病并减少损失。Mazen说，注射疫苗接种可能是昂贵且难以管理的。

The company said this is why it is now developing a product that offers transformative vaccine technology where the animals don’t even know they are being vaccinated.

By administering the vaccine with feed, challenges associated with finding labor to administer injectable vaccines and other issues such as broken needles in the animal or accidental vaccination of the worker are eliminated. Oral vaccines allow for cost-effective disease prevention with improved animal welfare.

Mazen’s oral vaccines are produced via recombinant protein production in corn. The technology platform leverages many years of breakthrough R&D led byJohn HowardMazen联合创始人和植物重组蛋白质生产的专家。

使用该技术开发的疫苗有望比传统的牲畜和伴侣动物的传统注射疫苗更具成本效益和方便。

“这项技术可以通过预防疾病而不是治疗来帮助实现更好的动物健康，并改善经济学，管理和可持续性。”Mazen首席执行官Jenny Filbey.

First vaccine designed for PEDv

Sibbel在小组讨论中指出，Mazen的铅口口服疫苗开发是为了预防猪流行腹泻病毒(PEDv).

PEDV疫苗目前正在进行USDA批准所需的关键疗效研究。该公司还正在扩大疫苗的商业生产。

"We're going to feed that vaccine to pregnant females who are going to nurse the pigs and protect the pigs against PEDv," said Sibbel. "That sounds a little bit like Star Wars, doesn't it?"

Mazen的管道已经进行了持续的概念验证研究，该研究对家禽中的球虫病和开发的第三个专有产品（也是为家禽）进行的。

A系列资金将用于支持PEDV产品的推出，管道产品的开发，向管道增加新产品，并向团队增加新成员。

疫苗的大约一年了

Sibbel said the industry will have to wait about a year before the product is ready.

"We're really the first company doing this," he said. "It's very exciting. We've been successful at digestive enzymes. We've been successful at protective antibodies. We've looked at fungal antibodies, we looked at bacterial antigens, fungal antigens -- this this technology is very novel and amazing."

西贝尔说，马祖（Mazen）已经进入了2 1/2年的计划大约18个月，以获得其第一个许可证，“一切都在正常。”

与肯特公司的合作伙伴关系。

Mazen's business plan to get the vaccine to market includes an exclusive partnership with肯特公司.

"We've been partners now in this space for about eight or nine months," said Sibbel. "Kent is our one of our distribution and marketing partners. They bring a lot to the table."

Mazen宣布收购1100万美元

5月25日，Mazen宣布已关闭一轮超过1100万美元的系列。

The round was led by Fall Line Capital and joined by all the Seed investors, including Next Level Ventures, Kent Corp., Ag Startup Engine, Ag Ventures Alliance, ISAV and Summit Ag.

In addition, new investors, AgFunder, 1330 Investments, Addison Laboratories, SLO Seeds Ventures and Cal Poly Ventures also participated in the financing.

“我很高兴能使Fall Line Capital带领我们的系列赛。他们相信我们经验丰富的团队和变革技术，并分享我们对积极增长的愿景。”

“我也很高兴我们所有的种子投资者继续在财务和社区中为我们提供支持。我们有很多投资者。”

Eric O’Brien，联合创始人兼董事总经理秋天的资本说，马祖（Mazen）是分子农业技术的最前沿，该技术利用植物作为重组蛋白和其他高价值分子的自然生产工厂。

"This novel approach has huge advantages in cost versus precision fermentation in expensive bioreactors or more traditional vaccine production methods," said O'Brien.

“我们很高兴能与Mazen合作，因为他们在动物健康方面开创了全新的可持续技术。”

—丽莎刀刀